GSK received approval from the Food and Drug Administration for Blujepa to be used as a treatment for some urinary tract infections. Blujepa, or gepotidacin, was approved to treat uncomplicated ...

GSK, led by boss Emma Walmsley (pictured), is using the data of 1.4m adults aged 65 and 66 to examine the impact of its ...

(Alliance News) - GSK on Tuesday said its urinary tract infection treatment gepotidacin, under the brand name Blujepa, has been approved in the US.

UK pharma major GSK (LSE: GSK) today announced a major new research collaboration with the UK Dementia Research Institute (UK ...

For much of her early career, Shobie Ramakrishnan called Silicon Valley home. GSK’s chief digital and technology officer ...

As of December 31, 2024, AnaptysBio had cash, cash equivalents, and investments greater than $420 million and anticipates ...

Anaptys has cash, cash equivalents and investments greater than $420 million as of December 31, 2024, and anticipates receipt of a $75 million commercial sales milestone payment from GSK in 2025 or ...

Farther Finance Advisors LLC decreased its holdings in shares of GSK plc (NYSE:GSK – Free Report) by 27.4% during the fourth ...

GSK plc (LON:GSK – Get Free Report)’s share price passed above its two hundred day moving average during trading on Thursday ...

Shares in the consumer health group - originally a joint venture between Pfizer and GSK - are up nearly a fifth since it joined the stock market in 2022.